A patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trial
Janssen's Elena Diez and Odyssey Therapeutics' Gary Glick share advice on success factors for pharma - biotech partnerships, and more
Kojin Therapeutics Chairman & CEO Harvey Berger shares an update on the company's progress and talks about the funding environment for earlier stage companies in biotech
Transcriptional regulation in disease: opportunities, challenges, and the future
A father and patient advocate discuss Canavan disease and a daughter's experience on a gene therapy clinical trial
Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR
George Church on founder led companies, synthetic biology technologies, the future, and more
Gene therapy experts TJ Cradick and Kate Excoffon discuss using AAV gene therapy for cystic fibrosis
Immuno-Oncology experts Zhen Su and Kristen Hege discuss the latest in the field and preview #SITC24
.png){kind=logo}
